Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
NCT01143662Phase 2Completed
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Jul 2010
- Primary completion
- Apr 2011
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (4 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoint: Efficacy at 24 weeks. Started Jul 2010; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01143662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01143662.